EA201791562A1 - Антигены цитомегаловируса и их применения - Google Patents

Антигены цитомегаловируса и их применения

Info

Publication number
EA201791562A1
EA201791562A1 EA201791562A EA201791562A EA201791562A1 EA 201791562 A1 EA201791562 A1 EA 201791562A1 EA 201791562 A EA201791562 A EA 201791562A EA 201791562 A EA201791562 A EA 201791562A EA 201791562 A1 EA201791562 A1 EA 201791562A1
Authority
EA
Eurasian Patent Office
Prior art keywords
applications
cytomegalovirus antigens
proteins
cytomegalovirus
antigens
Prior art date
Application number
EA201791562A
Other languages
English (en)
Other versions
EA038250B1 (ru
Inventor
Андреа Карфи
Клаудио Циферри
И Син
Original Assignee
Глаксосмитклайн Байолоджикалс Са
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Глаксосмитклайн Байолоджикалс Са filed Critical Глаксосмитклайн Байолоджикалс Са
Publication of EA201791562A1 publication Critical patent/EA201791562A1/ru
Publication of EA038250B1 publication Critical patent/EA038250B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/082—Hepadnaviridae, e.g. hepatitis B virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/25—Varicella-zoster virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Согласно данному изобретению предложены модифицированные белки gL цитомегаловируса (CMV) и комплексы, содержащие белки gL. Модифицированные белки gL остаются интактными и способны образовывать комплексы с другими белками CMV.
EA201791562A 2015-01-22 2016-01-22 Рекомбинантный белок gl цитомегаловируса с мутацией в сайте распознавания протеазой, которая уменьшает протеазное расщепление EA038250B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15152221.6A EP3048114A1 (en) 2015-01-22 2015-01-22 Cytomegalovirus antigens and uses thereof
PCT/IB2016/050335 WO2016116904A1 (en) 2015-01-22 2016-01-22 Cytomegalovirus antigens and uses thereof

Publications (2)

Publication Number Publication Date
EA201791562A1 true EA201791562A1 (ru) 2018-04-30
EA038250B1 EA038250B1 (ru) 2021-07-29

Family

ID=52434568

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201791562A EA038250B1 (ru) 2015-01-22 2016-01-22 Рекомбинантный белок gl цитомегаловируса с мутацией в сайте распознавания протеазой, которая уменьшает протеазное расщепление

Country Status (24)

Country Link
US (2) US10167321B2 (ru)
EP (3) EP3048114A1 (ru)
JP (1) JP6717836B2 (ru)
KR (1) KR20170100039A (ru)
CN (1) CN107531761B (ru)
AU (2) AU2016210548B2 (ru)
BE (1) BE1023087B1 (ru)
BR (1) BR112017015567A2 (ru)
CA (1) CA2974041C (ru)
DK (1) DK3247722T3 (ru)
EA (1) EA038250B1 (ru)
ES (1) ES2937959T3 (ru)
FI (1) FI3247722T3 (ru)
HR (1) HRP20230177T1 (ru)
HU (1) HUE061175T2 (ru)
IL (1) IL253366B (ru)
LT (1) LT3247722T (ru)
MX (1) MX2017009538A (ru)
PL (1) PL3247722T3 (ru)
PT (1) PT3247722T (ru)
SG (1) SG11201705740UA (ru)
SI (1) SI3247722T1 (ru)
WO (1) WO2016116904A1 (ru)
ZA (1) ZA201704912B (ru)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2569436B8 (en) * 2010-05-14 2019-10-30 Oregon Health & Science University Recombinant hcmv and rhcmv vectors and uses thereof
CA2832109C (en) 2011-06-10 2021-07-06 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
WO2016011293A1 (en) 2014-07-16 2016-01-21 Oregon Health & Science University Human cytomegalovirus comprising exogenous antigens
CN114317611A (zh) 2015-02-10 2022-04-12 俄勒冈健康与科学大学 可用于产生非典型cd8+t细胞应答的方法和组合物
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
MA42502A (fr) 2015-07-21 2018-05-30 Modernatx Inc Vaccins contre une maladie infectieuse
EP3364950A4 (en) 2015-10-22 2019-10-23 ModernaTX, Inc. VACCINES AGAINST TROPICAL DISEASES
WO2017070613A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Human cytomegalovirus vaccine
JP7133468B2 (ja) 2015-11-20 2022-09-08 オレゴン・ヘルス・アンド・サイエンス・ユニバーシティ マイクロｒｎａ認識エレメントを含むｃｍｖベクター
US11318197B2 (en) 2016-03-03 2022-05-03 Duke University Compositions and methods for inducing HIV-1 antibodies
US11246920B2 (en) 2016-03-03 2022-02-15 Duke University Compositions and methods for inducing HIV-1 antibodies
CA3039089A1 (en) 2016-10-03 2018-04-12 Duke University Methods to identify immunogens by targeting improbable mutations
SG11201903340TA (en) 2016-10-18 2019-05-30 Univ Oregon Health & Science Cytomegalovirus vectors eliciting t cells restricted by major histocompatibility complex e molecules
WO2018075980A1 (en) 2016-10-21 2018-04-26 Modernatx, Inc. Human cytomegalovirus vaccine
EP3582790A4 (en) 2017-02-16 2020-11-25 ModernaTX, Inc. VERY POWERFUL IMMUNOGENIC COMPOSITIONS
US20230248820A1 (en) 2017-04-19 2023-08-10 Glaxosmithkline Biologicals, S.A. Modified cytomegalovirus proteins and stabilized complexes
WO2019055807A1 (en) 2017-09-14 2019-03-21 Modernatx, Inc. RNA VACCINES AGAINST ZIKA VIRUS
US11773144B2 (en) 2017-10-02 2023-10-03 Duke University Mosaic HIV-1 envelopes to induce ADCC responses
US11771755B2 (en) 2018-02-28 2023-10-03 University Of Washington Self-asssembling nanostructure vaccines
BR112021006812A2 (pt) * 2018-10-17 2021-07-20 Glaxosmithkline Biologicals S.A. proteínas e complexos estabilizados modificados do citomegalovírus
CN109627330A (zh) * 2018-12-18 2019-04-16 马鞍山史记动物健康管理有限公司 一种猪伪狂犬病毒高效价阳性血清制备方法
US20230201334A1 (en) 2019-07-24 2023-06-29 Glaxosmithkline Biologicals Sa Modified human cytomegalovirus proteins
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
WO2023144665A1 (en) 2022-01-28 2023-08-03 Glaxosmithkline Biologicals Sa Modified human cytomegalovirus proteins

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
WO1991006666A1 (en) 1989-11-06 1991-05-16 Cell Genesys, Inc. Production of proteins using homologous recombination
EP2037959B1 (en) 2006-06-07 2016-01-27 The Trustees Of Princeton University Cytomegalovirus surface protein complex for use in vaccines and as a drug target
MX2011000543A (es) * 2008-07-16 2011-04-27 Inst Research In Biomedicine Anticuerpos neutralizantes de citomegalovirus humano y uso de los mismos.
MX2012002723A (es) 2009-09-02 2012-04-11 Novartis Ag Composiciones inmunogenicas que incluyen moduladores de la actividad de receptores tipo toll.
BR112013000391B8 (pt) 2010-07-06 2022-10-04 Novartis Ag Composição de emulsão catiônica de óleo em água e seu uso
EP4098325A1 (en) 2010-10-11 2022-12-07 GlaxoSmithKline Biologicals S.A. Antigen delivery platforms
RU2649133C2 (ru) 2011-07-06 2018-03-29 Новартис Аг Катионные эмульсии масло-в-воде
TWI570240B (zh) * 2011-09-09 2017-02-11 默沙東公司 作為細胞巨大病毒疫苗之條件式複製ｃｍｖ
ES2753138T3 (es) 2012-07-06 2020-04-07 Glaxosmithkline Biologicals Sa Complejos de proteínas de citomegalovirus
MX2015005505A (es) * 2012-10-30 2016-01-08 Redvax Gmbh Vacunas basadas en particular recombinantes contra la infeccion de citomegalovirus humano.
PL3083677T3 (pl) 2013-12-20 2020-03-31 Novartis Ag Nowe komórki eukariotyczne i sposoby rekombinowanej ekspresji produktu będącego przedmiotem zainteresowania
AU2014369175B2 (en) 2013-12-20 2017-03-02 Novartis Ag Novel eukaryotic cells and methods for recombinantly expressing a product of interest
EP3015475A1 (en) 2014-10-31 2016-05-04 Novartis AG Mammalian cells expressing cytomegalovirus antigens
EP3047856A1 (en) 2015-01-23 2016-07-27 Novartis AG Cmv antigens and uses thereof

Also Published As

Publication number Publication date
US20190276498A1 (en) 2019-09-12
CN107531761B (zh) 2022-01-14
EP3247722A1 (en) 2017-11-29
BR112017015567A2 (pt) 2018-03-13
KR20170100039A (ko) 2017-09-01
US10167321B2 (en) 2019-01-01
ZA201704912B (en) 2018-12-19
BE1023087A1 (fr) 2016-11-18
EP3247722B1 (en) 2022-11-30
CA2974041A1 (en) 2016-07-28
AU2018226521B2 (en) 2019-10-31
EP4180056A1 (en) 2023-05-17
MX2017009538A (es) 2017-11-02
EA038250B1 (ru) 2021-07-29
IL253366B (en) 2022-03-01
FI3247722T3 (fi) 2023-03-17
LT3247722T (lt) 2023-02-10
IL253366A0 (en) 2017-09-28
DK3247722T3 (da) 2023-01-30
ES2937959T3 (es) 2023-04-03
HUE061175T2 (hu) 2023-05-28
CA2974041C (en) 2023-04-04
SI3247722T1 (sl) 2023-04-28
PL3247722T3 (pl) 2023-03-20
AU2016210548B2 (en) 2018-11-08
CN107531761A (zh) 2018-01-02
WO2016116904A1 (en) 2016-07-28
SG11201705740UA (en) 2017-08-30
AU2016210548A1 (en) 2017-08-10
EP3048114A1 (en) 2016-07-27
HRP20230177T1 (hr) 2023-04-14
JP2018504117A (ja) 2018-02-15
BE1023087B1 (fr) 2016-11-18
AU2018226521A1 (en) 2018-09-27
US20170369532A1 (en) 2017-12-28
JP6717836B2 (ja) 2020-07-08
PT3247722T (pt) 2023-01-31

Similar Documents

Publication Publication Date Title
EA201791562A1 (ru) Антигены цитомегаловируса и их применения
CY1124004T1 (el) Υποδορια σκευασματα αντισωματων αντι-cd38 και οι χρησεις τους
CL2019000424A1 (es) Anticuerpos anti-tigit, anticuerpos anti-pvrig y combinaciones de estos.
EA202092435A2 (ru) Моноклональные антитела против bcma
MX2022008781A (es) Anticuerpos que se unen a interleucina 8 (il-8) y sus usos.
PH12017502180A1 (en) Tau-binding antibodies
BR112019012343A2 (pt) anticorpos il-11ra
EA201891338A1 (ru) Композиции и способы для иммуноонкологии
EA201792467A1 (ru) Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены
EA201791164A1 (ru) Гетеродимерные антитела, связывающие cd3 и cd38
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
EA201791139A1 (ru) Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены
EA201691991A1 (ru) Мультиспецифические антитела
NZ725568A (en) Modified j-chain
CY1124425T1 (el) Συνθεσεις οι οποιες περιλαμβανουν συζευγματα φαρμακου αντισωματος-δουοκαρμυκινης
EA201690314A1 (ru) Анти-garp-белок и его применения
FR3021319B1 (fr) Peptides, compositions les comprenant et utilisations notamment cosmetiques
PH12017502207A1 (en) Tau-binding antibodies
EA201992232A1 (ru) Композиции и способы для иммуноонкологии
PH12018550160A1 (en) NEW ANTI-SIRPa ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONS
EA201792612A1 (ru) 6-аминохинолин-3-карбонитрилы в качестве модуляторов cot
EA201591279A1 (ru) Новые фрагменты антител, их композиции и способы применения
EA201792492A1 (ru) Aml-антигены и их применение
EA201990505A1 (ru) Анти-tigit антитела, анти-pvrig антитела и их комбинации
UA107518U (uk) Інформаційна система